Rimon

Ping Wang, J.D.; M.D.

Partner

Intellectual Property, Patent Counseling and Prosecution, Life Sciences, Intellectual Property Litigation
Washington, D.C.
(202) 519-2151

EDUCATION

University of New Hampshire, Franklin Pierce Law Center

J.D.

Kunming Medical University

M.D.

PREVIOUS EXPERIENCE

  • Morris, Manning & Martin, LLP (Partner)
  • Hunton Andrews Kurth LLP (Partner)

    ADMISSIONS

  • District of Columbia
  • State of Maryland

    Languages

  • English
  • Mandarin

Dr. Ping Wang focuses her practice on all aspects of intellectual property, including patent prosecution, inter partes review, post grand review, interference practice, counseling and opinions regarding patentability, patent invalidity, freedom-to-operate, infringement, design around, and diligence work in connection with mergers and acquisitions in the biotechnology industry.

Dr. Wang also handles IPR, patent infringement, and other litigation matters, as well as licensing negotiations, information technology and academic agreements, and acquisitions of capital for entrepreneurs, start-ups, and institutions. She has played a lead role in inter partes review, which is strengthened by her extensive prior patent experience.  Dr. Wang has well-established relationships throughout the world which enables swifter patent prosecution outside of the United States. She is business-oriented and gives detailed attention to developing client concepts into complex and complete applications.

Dr. Wang has extensive experience securing broad scope protection for start-ups, universities, medium and large corporations globally. She negotiates and handles business transactions on behalf of her clients, with a particular focus on business negotiations and transactions between the United States and China.  She is knowledgeable about all aspects of life science and has experience providing legal advice to clients in the pharmaceuticals, biotechnology, chemical/organic chemistry, medical devices, and artificial intelligence industries.

Awards and Recognition

  • IP Star, National and Washington, D.C., 2020-2021
  • Managing Intellectual Property, IP Stars, Patent Star, 2020
  • IAM Global Leaders, Patent Prosecution, 2020-2021
  • IAM Patent 1000, Patent Prosecution, 2012-2022
  • Chambers USA, Intellectual Property: Patent Prosecution 2021- 2022
  • Lawdragon 500, Leading Litigators in America, 2022
  • National Law Journal, Intellectual Property Trailblaizer, March 2019
  • US Legal 500, Leading Patents: Licensing, and Patents: Prosecution Lawyer
  • Elliot Stellar Award from the Philadelphia Chapter, Society for Neuroscience
  • Lapides Award from the American Urological Society

Professional Associations

  • American Bar Association
  • American Intellectual Property Law Association – Interference Committee, Biotechnology Committee, Licensing Committee
  • American Health Law Association
  • American International Law Association
  • United States Patent and Trademark Office, Biotechnology, Chemical and Pharmaceutical Partnership
  • Society for Neuroscience
  • International Brain Research Organization

Legal Publications

  • Coronavirus Drug Shows Global Hurdles to Patent Protection, Co-Author, Law360, February 2020
  • Gene Therapy Policies Can Strike an Ethical Balance, Co-Author, Law360, May 2019
  • New USPTO Guidance May Help Diagnostics Patents, Co-Author, Law360, April 2019
  • New Proposed Rules Regarding Government Rights in Federally Funded Research: Bayh-Dole Act, Co-Author, The National Law Review, February 21, 2017
  • Federal Circuit Clarifies the Steps in Biosimilars Dance, Co-Author, The National Law Review, July 24, 2015
  • Presumption of Validity Triumphs over a Good-Faith Belief of Invalidity, Co-Author, The National Law Review, May 28, 2015
  • Post Exclusivity Issues For Biologics, Co-Author, The National Law Review, January 3, 2015 – Murray
  • The Myriad Decision in the U.S. Supreme Court, Co-Author, The National Law Review, July 11, 2012
  • Is an Isolated DNA Patentable?, Co-Author, The National Law Review, October 27, 2011

Scientific Publications

  • Luthin, G.R., Wang, P., Zhou, H., Dhanasekaran, D., and Ruggieri, M. Role of m1 receptor-G Protein coupling in cell proliferation in the prostate. Ann. N.Y. Acad. Sci. Vo160, Nos. 13/14 (1997)
  • Tian, X.H., Gu, J.F., Sun, C.P., and Wang, P. An EPR study of the neuroprotective effect of the sulfated polysaccaride from Laminaria Japonica. Soc. Neurosci. 15: 2187 (1997)
  • Wang, P., Dhanasekaran, N.E. and Luthin, G.R. ERK activation and cellulary proliferation in response to muscarinic acetylcholine receptor agonist. Ann N.Y. Acad. Sci. (1996)
  • Wang, P., Luthin, G.R., and Ruggieri, M.R. Muscanrinic acetylcholine receptors mediating urinary bladder contractility and coupling to GTP binding proteins. J. Pharmacal. Expt. Ther. 273:959-966 (1995)
  • Wang, P., Dhanasekaran, N.D. and Luthin, G.R. ERK activation and cellular proliferation in response to muscarinic acetylcholine receptor agonist. Receptor Classification, Verona, Italy (1995)
  • Ruggieri, M.R., Colton, M.D., Wang, P., Smyth, R.J., Pontari, M.A., and Luthin, G.R. Human prostate muscarinic receptor subtypes. J. Pharmacal.Expt. Ther. 274:976-982 (1995)
  • Wang, P., Dhanasekaran, N.D. and Luthin, D.R. ERK activation and cellular proliferation in response to muscarinic acetylcholine receptor agonist. Receptor Classification, Verona, Italy (1995)
  • Ruggieri, M.R., Colton, M.D., Wang, P., Smyth, R.J., Ontari, M.A., and Luthin, G.R. Human prostate muscarinic receptor subtypes studied. Am. Urol. Assn. Today 8:1-13 (1995)
  • Wang, P., Luthin, G.R., and Ruggieri, M.R. Muscarinic acetylcholine receptor subtypes mediating urinary bladder contractility and coupling to GTP binding proteins. J. Urol. Survey Section (1995)
  • Wang, P. Ruggieri, M.R., and Luthin, G.R. Biochemical analysis of urinary bladder muscarinic receptor subtypes. J. Urol., Soc. Basic Urol. Res. Suppl., San Francisco, CA (1994)
  • Colton, M.D., Wang, P., Cawley, T.A., Luthin, G.R., and Ruggieri, M.R. Effect of experimental hyperreflexia on rabbit bladder muscarinic receptor subtypes. J. Urol. 151 :482A (1994)
  • Ruggieri, M.R., Colton, M.D., Wang, P., Smyth, R.J., Pontari, M.A., and Luthin, G.R. Human prostate muscarinic receptor subtypes. J. Urol. 151:380A (1994)
  • Ruggieri, M.R., Colton, M.D., Wang, P., Smyth, R.J., Pontari, M.A., and Luthin, G.R. Human prostate muscarinic receptor subtypes. Soc. Basic Urol. Res., Houston, TX (1993)
  • Smyth, R.J., Ruggieri, M.R., Colton, M.D., Wang, P., Shickley, T.J., and Luthin, G.R. Prostate gland contains high levels of the m1 subtype of muscarinic receptor. Soc. Neurosci. 19:1786 (1993)
  • Wang, P., and Luthin, G.R. Stable association of m3 muscarinic receptors and G proteins. Soc. Neurosci. 19:1768 (1993)
  • Cawley, T.A., Wang, P., Ruggieri, M.R., and Luthin, G.R. Muscarinic acetylcholine receptors in urinary bladder. Soc. Neurosci. 19:1767 (1993)
  • Ruggieri, M.R., Cawley, T.A., Wang, P., Hicks, S.E., and Luthin, G.R. Urinary bladder muscarinic receptor subtypes; effect of chronic neuroleptic treatment. Incontinence Soc., Halifax, Nova Scotia (1992)

EDUCATION

University of New Hampshire, Franklin Pierce Law Center

J.D.

Kunming Medical University

M.D.

PREVIOUS EXPERIENCE

  • Morris, Manning & Martin, LLP (Partner)
  • Hunton Andrews Kurth LLP (Partner)

    ADMISSIONS

  • District of Columbia
  • State of Maryland

    Languages

  • English
  • Mandarin